Global Male Hypogonadism Epidemiology and Patient Flow Analysis - 2017
Fore Pharma announced the results of its Male Hypogonadism patients study in a new report ‘Global Male Hypogonadism Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Male Hypogonadism epidemiology, Male Hypogonadism diagnosed patients, and Male Hypogonadism treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Male Hypogonadism derived from epidemiological analysis, percentage of patients diagnosed with Male Hypogonadism, and percentage of patients treated with a therapy.
The study helps executives estimate Male Hypogonadism market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Male Hypogonadism prevalence, Male Hypogonadism diagnosis rate, and Male Hypogonadism treatment rate for the period 2016 - 2025. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.